Skip to main content
Premium Trial:

Request an Annual Quote

Sebia, Netherlands Universities to Develop Test for Disease Status in Patients With Multiple Myeloma

NEW YORK ─ Paris-based Sebia on Wednesday announced a license agreement with universities in the Netherlands to develop a sensitive mass spectrometry-based minimal residual disease (MRD) test for multiple myeloma and related conditions.

The collaboration involving Sebia, the Erasmus University Medical Center in Rotterdam, and the Radboud University Medical Center in Nijmegen will enable Sebia to develop a clinical laboratory test that provides MRD status directly from patients' serum samples or serum-protein electrophoresis gels, the organizations said.

Financial and other terms of the agreement were not disclosed.

"Through personalized diagnostics on one drop of blood, we can create a patient-friendly alternative to monitor MRD in myeloma patients," Hans Jacobs, medical immunologist and head of the Dutch M-protein reference center at Radboud UMC, said in a statement. "This allows dynamic monitoring of patients with detailed responses, which is crucial for early detection of disease relapse."